Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research

Post Reply
User avatar
Posts: 3222
Joined: Fri Jun 26, 2020 4:36 am
Location: The Bunker

Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research

Post by TimGDixon »

Big congratulations to our dear friend, colleague, and science team member Dr. Francesco Marincola on his appointment with Gilead as Senior Vice President and Global Head of Cell Therapy Research. Way to go Franco!!!! ... y-research

January 19, 2021

Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
-- Research Veteran Brings More than 30 Years of Industry and NIH Experience to Kite Leadership Team --

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr. Marincola will lead Kite’s Research organization across hematological malignancies and solid tumors.

“Franco’s proven track record in oncology and robust research experience that spans the NIH to industry will be critical to the targeting and acceleration of our research efforts in CAR T and beyond,” said Christi Shaw, Chief Executive Officer of Kite. “As the cell therapy leader, we are thrilled to welcome Franco to our team and are confident that his exceptional skills and expertise will best position our research to discover potentially life-saving therapies for patients in need.”

Dr. Marincola joins Kite from Refuge Biotechnologies Inc., where he was President and Chief Scientific Officer, responsible for the development and implementation of research and clinical development of synthetic biology strategies for adoptive cell therapy products and lead therapeutic programs based on nuclease deactivated CRISPR circuits. He is also a National Institutes of Health (NIH) tenured senior investigator in cancer immunotherapy and biomarker research, and spent 23 years at the NIH, including 15 years as the Chief of the Infectious Disease and Immunogenetics Section at the NIH Clinical Center. Previously, he also served as a distinguished research fellow in immune oncology discovery at AbbVie and as Chief Research Officer at Sidra Research in Doha, Qatar. The former President of the Society for Immunotherapy of Cancer (SITC; 2013-2014), he currently serves as Editor-in-Chief for several prominent peer-reviewed publications, including Journal of Translational Medicine, Translational Medicine Communications and Immunotherapy, and is the author of more than 600 peer-reviewed publications.

“It is an honor to bring my experience to an industry-leading team that is working to make cell therapies with curative intent available to patients,” said Dr. Marincola. “I look forward to helping build and diversify our research efforts in support of this mission.”

About Kite

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California, with commercial manufacturing operations in North America and Europe. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at
Posts: 184
Joined: Sat Jun 27, 2020 5:33 am

Re: Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research

Post by rrao11 »

That is incredible News! This goes to show that we have an extremely talented and respected researcher and scientist on our SAB.


I remember when Gilead surprised the world by acquiring Kite Pharma for $32bil. We all know all the Pharma world is interested and eagerly looking for allogenic - universal, off the shelf immunotheray - as individualized cell therapies are complex and costly. And guess what? We have Stemcells!!! May be, just may be, they’ll look into our StemVacs?

This is awesome news, nonetheless!

Posts: 1312
Joined: Fri Jun 26, 2020 8:27 am

Re: Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research

Post by curncman »

Excellent observation Rao! Dr.Franco knows everything about TSOIs STEMVACS as he is on SAB of TSOI. I wonder his association with TSOI was not mentioned on the GILEADs PR yesterday???🙁🙁🙁🙁🙁🙁🙁🙁🙁🙁🙁🙁🙁🙁🙁🙁🙁🙁 Any guesses!!!!I know since they don't want to drop an hint to the market that they. R going to license STEMVACS and NANOSTILBENE!😉😉😉😉😉😉😉😉😉😉😉😜😜😜😜😜😜😜😜😜😜😜👍😰😰😰😰😰😰😰😰😰😰
User avatar
Posts: 3222
Joined: Fri Jun 26, 2020 4:36 am
Location: The Bunker

Re: Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research

Post by TimGDixon »

Thanks for the nice comments. Let me set the record straight though - i've always been truthful and transparent here - there is no current talks between TSOI and Gilead/Kite in relationship to any of our technology. Doesn't mean the future won't bring that but nothing about his new employment is related to us. We are just overjoyed for our dear friend and colleague to land a great position.

This is who Franco is and if you really want to know what influences us watch this video - never let anyone tell you never...

What's The Future of Cancer Immunotherapy? World Renowned Cancer Expert Shares His Perspective
User avatar
Posts: 3222
Joined: Fri Jun 26, 2020 4:36 am
Location: The Bunker

Re: Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research

Post by TimGDixon »

I saw some folks posting that Franco just joined up with us - no - Franco has been with me since 2015 when Tom and I discovered StemVacs1 (stemvacs 1 is an autologous cell (self)) and then we proceeded to Mexico and treated 10 patients in clinical trial. Three years later when Franco's first term on SAB ran out he re-enlisted and the press releases surrounding that are pasted below.

TSOI isn't a video game that provides instant gratification - these "things" you are all learning about we've been working on a long time and have invested our entire lives into them. Everything has its place and time and when it comes to the regulatory world of FDA and that clock can run very slow... if this stuff could be answered overnight, well, it would already be done but thats not the case - Bio takes a long time - know what you own friends and why - Bio is not pharma - pharma doesn't invent anything - they only license or buy things - but they do not invent - so there is no pharma really without folks like us - a husband and wife invented the Pfizer vaccine - not Pfizer.

So in the end we are very happy for Franco getting hired by Gilead and it certainly doesn't hurt having an insider in pharma :lol: something CEO's like me dream about...You gotta love Franco's quote "I am excited to work with the Company at developing StemVacs, a cell therapy product, and NanoStilbene, an inexpensive, nanotechnology based nutraceutical that has shown great promise in current studies".

Since 2018 we continued to develop StemVacs into its second generation which is the allogeneic form (universal donor) you have recently heard about. This is an off-the-shelf immunotherapy for the "masses" that can be administered both non-antigen-specific as well as antigen specific. So as i've said before first chance i get i will be in Mexico conducting a 10 patient Phase 1 to proof the concept, publish the results, submit to FDA under 312.120 and move to USA IND Phase I/II. We have the clinic lined up, the manufacturing, investigator, and IRB approval - all i need is $300k and 10 humans. Try and do 10 patients in the USA for $300k.

Oceanside, CA -- October 21, 2015 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today that Francesco M Marincola, MD, FACS, has been appointed to our Scientific Advisory Board.

Dr. Marincola previously held the position of Chief of the Infectious Disease and Immunogenetics Section (IDIS) and Tenured Senior Investigator at the U.S. National Institutes of Health (NIH). He was also Director of the Immunogenetics Program, Department of Transfusion Medicine, Director of the Federation of Clinical Immunology Societies (FOCIS) Center for Excellence and Co-Director of the Trans-NIH Center for Human Immunology.

Dr. Marincola received his MD summa cum laude from the University of Milan and his surgery training from Stanford University. Dr. Marincola is the second most cited scientist in the field of melanoma during the last ten years, with 55 papers cited 3,704 times to date. His research interest is primarily translational and focuses on the development of strategies for the dynamic study of patients response to therapies. His approach has deepened understanding of the mechanisms leading to rejection of tumors, allograft, graft versus host disease and leading to the development of autoimmunity.

With the appointment of Dr. Marincola to our Scientific Advisory Board who now joins Dr. Michael G. Agadjanyan, Dr. Santosh Kesari, and Dr. Harry Lander, we truly have a world class team of scientists to identify and discuss significant emerging regulatory, research and scientific issues and trends and competitive activity, including their potential impacts on any Company programs, plans, or policies relating to its development programs and research activities said Timothy Dixon, President and CEO of Therapeutic Solutions.


OCEANSIDE, Calif., July 23, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced the appointment of Dr. Francesco Marincola to the Company's Scientific Advisory Board. Dr. Marincola is currently Chief Science Officer at Refuge Biotechnologies, Menlo Park, California. Most recently, he served as a distinguished research fellow and strategist for immune oncology discovery at AbbVie, Inc a 148 Billion Dollar Market Cap Company.

Other notable positions he held include leading programs at the Sidra Medical and Research Center in Qatar and the National Institutes of Health. He is currently leading worldwide efforts to understand the mechanism of cancer immune resistance such as the Society for the Immunotherapy of Cancer Task Force on Immune Responsiveness aimed at involving different areas of expertise besides immunology.

"We are very honored to be joined by such a visionary and leader in the area of cancer immunotherapy. Dr. Marincola was a believer and practitioner of immunotherapy, decades before the "Golden Era of Immunology" in which we currently are in," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "Dr. Marincola performed the initial work on tumor infiltrating lymphocytes and interleukin-2 immunotherapy, which served as the foundation for the numerous immunotherapeutic drugs that are currently approved by the FDA including checkpoint inhibitors and CAR-T cells."

Immunotherapy uses the patient's own immune system to kill cancer cells. Currently the FDA has approved two major classes of immunotherapy: 1. Checkpoint inhibitors such as Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, and Durvalumab, act to "take the brakes off" the immune system, resulting in immune hyperactivation and tumor regression; and 2. CAR-T cells, such as Yescarta and Kymriah, which are genetically engineered T cells programmed to selectively kill cancer cells.

"Despite the tremendous excitement of immunotherapy, the sad reality is that only about 20% of patients have responses to checkpoint inhibitors, and CAR-T cells are currently only applicable to patients with blood malignancies," said Dr. James Veltmeyer, the Company's Chief Medical Officer. "We at Therapeutic Solutions International are focusing on our StemVacs program, which seeks to train T cells to kill cancer stem cells utilizing dendritic cell technology, and NanoStilbene, a nutraceutical based augmenter of immunotherapy for which we received US Patent #9,682,047. We are excited to work with Dr. Marincola, one of the first to utilize immunotherapy, in order to accelerate clinical development of our approaches to cancer."

"While the concept of using the immune system as cancer therapy is accepted, there is a great need for novel approaches. I am excited to work with the Company at developing StemVacs, a cell therapy product, and NanoStilbene, an inexpensive, nanotechnology based nutraceutical that has shown great promise in current studies," stated Dr. Francisco Marincola. "The unique and practical therapeutics in development by Therapeutic Solutions International offer a fresh approach to current immunotherapies and I am excited to participate in their clinical translation."

Dr. Marincola graduated summa cum laude at the University of Milan, Medical School, Italy, and completed a general surgery residency with a focus in immunology at Stanford University. He was president of the Society for the Immunotherapy of Cancer and is the founding and current editor-in-chief of the Journal of Translational Medicine.
User avatar
Posts: 3222
Joined: Fri Jun 26, 2020 4:36 am
Location: The Bunker

Re: Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research

Post by TimGDixon »

This is not an exhaustive list of published papers of Thomas E Ichim but is representative of the level of science and associated collaborators who all work with TSOI one way or the other. Everyone from Franco Marincola to Santosh Kesari to Famela Ramos to Christopher Mizer to Feng Lin to Hong Ma to Boris Reznik to Javier Lopez to Amit Patel to Wei Ping Min and others - this is the academic prowess that drives TSOI. If you just add up Ichim, Kesari, and Marincola they have more than a combined 1,300 peer reviewed papers published. Is it making sense yet?

Josephs SF, Ichim TE, Prince SM, Kesari S, Marincola FM, Escobedo AR, Jafri
A. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. J Transl Med.
2018 Aug 31;16(1):242. doi: 10.1186/s12967-018-1611-7. PMID: 30170620; PMCID:

Ichim TE, O'Heeron P, Kesari S. Fibroblasts as a practical alternative to
mesenchymal stem cells. J Transl Med. 2018 Jul 27;16(1):212. doi:
10.1186/s12967-018-1536-1. PMID: 30053821; PMCID: PMC6064181.

Lin F, Ichim TE, Pingle S, Jones LD, Kesari S, Ashili S. Mesenchymal stem
cells as living anti-inflammatory therapy for COVID-19 related acute respiratory
distress syndrome. World J Stem Cells. 2020 Oct 26;12(10):1067-1079. doi:
10.4252/wjsc.v12.i10.1067. PMID: 33178392; PMCID: PMC7596438.

Tao Z, Li S, Ichim TE, Yang J, Riordan N, Yenugonda V, Babic I, Kesari S.
Cellular immunotherapy of cancer: an overview and future directions.
Immunotherapy. 2017 Jun;9(7):589-606. doi: 10.2217/imt-2016-0086. PMID:

Wagner SC, Riordan NH, Ichim TE, Szymanski J, Ma H, Perez JA, Lopez J, Plata-
Munoz JJ, Silva F, Patel AN, Kesari S. Safety of targeting tumor endothelial
cell antigens. J Transl Med. 2016 Apr 12;14:90. doi: 10.1186/s12967-016-0842-8.
PMID: 27071457; PMCID: PMC4830034.

Scarpone M, Kuebler D, Chambers A, De Filippo CM, Amatuzio M, Ichim TE, Patel
AN, Caradonna E. Isolation of clinically relevant concentrations of bone marrow
mesenchymal stem cells without centrifugation. J Transl Med. 2019 Jan
5;17(1):10. doi: 10.1186/s12967-018-1750-x. PMID: 30611285; PMCID: PMC6321705.

Dobrovolsky AP, Gedzun VR, Bogin VI, Ma D, Ichim TE, Sukhanova IA, Malyshev
AV, Dubynin VA. Beneficial effects of xenon inhalation on behavioral changes in
a valproic acid-induced model of autism in rats. J Transl Med. 2019 Dec
3;17(1):400. doi: 10.1186/s12967-019-02161-6. PMID: 31796043; PMCID: PMC6891980.

Alexandrescu DT, Riordan NH, Ichim TE, Kauffman CL, Kabigting F, Dutton CT,
Dasanu CA. On the missing link between inflammation and cancer. Dermatol Online
J. 2011 Jan 15;17(1):10. PMID: 21272501.

Wagner SC, Ichim TE, Ma H, Szymanski J, Perez JA, Lopez J, Bogin V, Patel
AN, Marincola FM, Kesari S. Cancer anti-angiogenesis vaccines: Is the tumor
vasculature antigenically unique? J Transl Med. 2015 Oct 29;13:340. doi:
10.1186/s12967-015-0688-5. PMID: 26510973; PMCID: PMC4625691.

Maslin B, Alexandrescu DT, Ichim TE, Dasanu CA. Newer developments in the
immunotherapy of malignant melanoma. J Oncol Pharm Pract. 2014 Feb;20(1):3-10.
doi: 10.1177/1078155212472702. Epub 2013 Feb 22. PMID: 23435643.

Ichim TE, Zheng X, Suzuki M, Kubo N, Zhang X, Min LR, Beduhn ME, Riordan NH,
Inman RD, Min WP. Antigen-specific therapy of rheumatoid arthritis. Expert Opin
Biol Ther. 2008 Feb;8(2):191-9. doi: 10.1517/14712598.8.2.191. PMID: 18194075.

Mizer JC, Ichim TE, Alexandrescu DT, Dasanu CA, Ramos F, Turner A, Woods EJ,
Bogin V, Murphy MP, Koos D, Patel AN. Exogenous endothelial cells as
accelerators of hematopoietic reconstitution. J Transl Med. 2012 Nov 21;10:231.
doi: 10.1186/1479-5876-10-231. PMID: 23171397; PMCID: PMC3543295.

Ichim TE, Solano F, Glenn E, Morales F, Smith L, Zabrecky G, Riordan NH.
Stem cell therapy for autism. J Transl Med. 2007 Jun 27;5:30. doi:
10.1186/1479-5876-5-30. PMID: 17597540; PMCID: PMC1914111.

Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, Kabigting
FD, Dasanu CA. Immunotherapy for melanoma: current status and perspectives. J
Immunother. 2010 Jul-Aug;33(6):570-90. doi: 10.1097/CJI.0b013e3181e032e8. PMID:
20551839; PMCID: PMC3517185.

Li M, Qian H, Ichim TE, Ge WW, Popov IA, Rycerz K, Neu J, White D, Zhong R,
Min WP. Induction of RNA interference in dendritic cells. Immunol Res.
2004;30(2):215-30. doi: 10.1385/IR:30:2:215. PMID: 15477662.

Ichim TE, Li M, Qian H, Popov IA, Rycerz K, Zheng X, White D, Zhong R, Min
WP. RNA interference: a potent tool for gene-specific therapeutics. Am J
Transplant. 2004 Aug;4(8):1227-36. doi: 10.1111/j.1600-6143.2004.00530.x. PMID:
15268723; PMCID: PMC7175948.

Dasanu CA, Ichim TE, Alexandrescu DT. Inherent and iatrogenic immune defects
in hairy cell leukemia: revisited. Expert Opin Drug Saf. 2010 Jan;9(1):55-64.
doi: 10.1517/14740330903427951. PMID: 20001754.

Marleau AM, Lipton JH, Riordan NH, Ichim TE. Therapeutic use of Aldara in
chronic myeloid leukemia. J Transl Med. 2007 Jan 25;5:4. doi:
10.1186/1479-5876-5-4. PMID: 17254347; PMCID: PMC1790884.

Ichim TE, Alexandrescu DT, Solano F, Lara F, Campion Rde N, Paris E, Woods
EJ, Murphy MP, Dasanu CA, Patel AN, Marleau AM, Leal A, Riordan NH. Mesenchymal
stem cells as anti-inflammatories: implications for treatment of Duchenne
muscular dystrophy. Cell Immunol. 2010;260(2):75-82. doi:
10.1016/j.cellimm.2009.10.006. PMID: 19917503.

Mikirova NA, Jackson JA, Hunninghake R, Kenyon J, Chan KW, Swindlehurst CA,
Minev B, Patel AN, Murphy MP, Smith L, Alexandrescu DT, Ichim TE, Riordan NH.
Circulating endothelial progenitor cells: a new approach to anti-aging medicine?
J Transl Med. 2009 Dec 15;7:106. doi: 10.1186/1479-5876-7-106. PMID: 20003528;
PMCID: PMC2804590.

Riordan NH, Ichim TE, Min WP, Wang H, Solano F, Lara F, Alfaro M, Rodriguez
JP, Harman RJ, Patel AN, Murphy MP, Lee RR, Minev B. Non-expanded adipose
stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med.
2009 Apr 24;7:29. doi: 10.1186/1479-5876-7-29. PMID: 19393041; PMCID:

Zhang Y, Fu J, Shi Y, Peng S, Cai Y, Zhan X, Song N, Liu Y, Wang Z, Yu Y,
Wang Y, Shi Q, Fu Y, Yuan K, Zhou N, Joshi R, Ichim TE, Min W. A new cancer
immunotherapy via simultaneous DC-mobilization and DC-targeted IDO gene
silencing using an immune-stimulatory nanosystem. Int J Cancer. 2018 Oct
15;143(8):2039-2052. doi: 10.1002/ijc.31588. Epub 2018 Aug 10. PMID: 29752722.

Li X, Lan X, Wang G, Liu Y, Zhao K, Lu SZ, Xu XX, Shi GG, Ye K, Zhang BR,
Zhao YM, Han HQ, Du CG, Ichim TE, Wang H. Skin Allografting Activates Anti-tumor
Immunity and Suppresses Growth of Colon Cancer in Mice. Transl Oncol. 2018
Aug;11(4):890-899. doi: 10.1016/j.tranon.2018.04.012. Epub 2018 May 21. PMID:
29793087; PMCID: PMC6041562.

Bockeria L, Bogin V, Bockeria O, Le T, Alekyan B, Woods EJ, Brown AA, Ichim
TE, Patel AN. Endometrial regenerative cells for treatment of heart failure: a
new stem cell enters the clinic. J Transl Med. 2013 Mar 5;11:56. doi:
10.1186/1479-5876-11-56. PMID: 23510656; PMCID: PMC3599750.

Ichim TE, Kesari S, Shafer K. Protection from chemotherapy- and antibiotic-
mediated dysbiosis of the gut microbiota by a probiotic with digestive enzymes
supplement. Oncotarget. 2018 Jul 20;9(56):30919-30935. doi:
10.18632/oncotarget.25778. PMID: 30112118; PMCID: PMC6089397.

Riordan NH, Chan K, Marleau AM, Ichim TE. Cord blood in regenerative
medicine: do we need immune suppression? J Transl Med. 2007 Jan 30;5:8. doi:
10.1186/1479-5876-5-8. PMID: 17261200; PMCID: PMC1796850.

Alexandrescu DT, Kauffman CL, Ichim TE, Riordan NH, Kabigting F, Dasanu CA.
Cutaneous sarcoidosis and malignancy: An association between sarcoidosis with
skin manifestations and systemic neoplasia. Dermatol Online J. 2011 Jan
15;17(1):2. PMID: 21272493.

Alexandrescu DT, Maslin B, Kauffman CL, Ichim TE, Dasanu CA. Malignant
melanoma in pigmented skin: does the current interventional model fit a
different clinical, histologic, and molecular entity? Dermatol Surg. 2013
Sep;39(9):1291-303. doi: 10.1111/dsu.12251. Epub 2013 Jun 24. PMID: 23795952.

Tullis RH, Duffin RP, Ichim TE, Joyce JA, Levin NW. Modeling hepatitis C
virus therapies combining drugs and lectin affinity plasmapheresis. Blood Purif.
2010;29(2):210-5. doi: 10.1159/000245649. Epub 2010 Jan 8. PMID: 20093829.

Ichim TE, Warbington T, Cristea O, Chin JL, Patel AN. Intracavernous
administration of bone marrow mononuclear cells: a new method of treating
erectile dysfunction? J Transl Med. 2013 Jun 9;11:139. doi:
10.1186/1479-5876-11-139. PMID: 23758954; PMCID: PMC3718667.

Dobrovolsky A, Ichim TE, Ma D, Kesari S, Bogin V. Xenon in the treatment of
panic disorder: an open label study. J Transl Med. 2017 Jun 13;15(1):137. doi:
10.1186/s12967-017-1237-1. PMID: 28610592; PMCID: PMC5470223.

Murphy MP, Wang H, Patel AN, Kambhampati S, Angle N, Chan K, Marleau AM,
Pyszniak A, Carrier E, Ichim TE, Riordan NH. Allogeneic endometrial regenerative
cells: an "Off the shelf solution" for critical limb ischemia? J Transl Med.
2008 Aug 19;6:45. doi: 10.1186/1479-5876-6-45. PMID: 18713449; PMCID:

Ichim TE, Harman RJ, Min WP, Minev B, Solano F, Rodriguez JP, Alexandrescu
DT, De Necochea-Campion R, Hu X, Marleau AM, Riordan NH. Autologous stromal
vascular fraction cells: a tool for facilitating tolerance in rheumatic disease.
Cell Immunol. 2010;264(1):7-17. doi: 10.1016/j.cellimm.2010.04.002. Epub 2010
Apr 8. PMID: 20537320.

Leal A, Ichim TE, Marleau AM, Lara F, Kaushal S, Riordan NH. Immune effects
of mesenchymal stem cells: implications for Charcot-Marie-Tooth disease. Cell
Immunol. 2008 May-Jun;253(1-2):11-5. doi: 10.1016/j.cellimm.2008.06.003. Epub
2008 Jul 15. PMID: 18627903.

Elabd C, Ichim TE, Miller K, Anneling A, Grinstein V, Vargas V, Silva FJ.
Comparing atmospheric and hypoxic cultured mesenchymal stem cell transcriptome:
implication for stem cell therapies targeting intervertebral discs. J Transl
Med. 2018 Aug 10;16(1):222. doi: 10.1186/s12967-018-1601-9. PMID: 30097061;
PMCID: PMC6086019.

Wagner SC, Ichim TE, Bogin V, Min WP, Silva F, Patel AN, Kesari S. Induction
and characterization of anti-tumor endothelium immunity elicited by ValloVax
therapeutic cancer vaccine. Oncotarget. 2017 Apr 25;8(17):28595-28613. doi:
10.18632/oncotarget.15563. PMID: 28404894; PMCID: PMC5438675.

Suzuki M, Zheng X, Zhang X, Zhang Y, Ichim TE, Min W. Regulation of allergy
with RNA interference. Crit Rev Immunol. 2009;29(6):443-68. doi:
10.1615/critrevimmunol.v29.i6.10. PMID: 20121695.

Darinskas A, Paskevicius M, Apanavicius G, Vilkevicius G, Labanauskas L,
Ichim TE, Rimdeika R. Stromal vascular fraction cells for the treatment of
critical limb ischemia: a pilot study. J Transl Med. 2017 Jun 19;15(1):143. doi:
10.1186/s12967-017-1243-3. Retraction in: J Transl Med. 2020 Feb 18;18(1):90.
PMID: 28629476; PMCID: PMC5477131.

Ichim TE, Solano F, Lara F, Rodriguez JP, Cristea O, Minev B, Ramos F, Woods
EJ, Murphy MP, Alexandrescu DT, Patel AN, Riordan NH. Combination stem cell
therapy for heart failure. Int Arch Med. 2010 Apr 14;3(1):5. doi:
10.1186/1755-7682-3-5. PMID: 20398245; PMCID: PMC3003238.

Ichim TE, Minev B, Braciak T, Luna B, Hunninghake R, Mikirova NA, Jackson
JA, Gonzalez MJ, Miranda-Massari JR, Alexandrescu DT, Dasanu CA, Bogin V, Ancans
J, Stevens RB, Markosian B, Koropatnick J, Chen CS, Riordan NH. Intravenous
ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med. 2011
Mar 4;9:25. doi: 10.1186/1479-5876-9-25. PMID: 21375761; PMCID: PMC3061919.

Zheng X, Suzuki M, Zhang X, Ichim TE, Zhu F, Ling H, Shunnar A, Wang MH,
Garcia B, Inman RD, Min WP. RNAi-mediated CD40-CD154 interruption promotes
tolerance in autoimmune arthritis. Arthritis Res Ther. 2010;12(1):R13. doi:
10.1186/ar2914. Epub 2010 Jan 26. PMID: 20102615; PMCID: PMC2875641.

Ichim TE, Solano F, Brenes R, Glenn E, Chang J, Chan K, Riordan NH.
Placental mesenchymal and cord blood stem cell therapy for dilated
cardiomyopathy. Reprod Biomed Online. 2008 Jun;16(6):898-905. doi:
10.1016/s1472-6483(10)60159-9. PMID: 18549704.

Ichim TE, Zhong Z, Mikirova NA, Jackson JA, Hunninghake R, Mansilla E, Marín
G, Núñez L, Patel AN, Angle N, Murphy MP, Dasanu CA, Alexandrescu DT, Bogin V,
Riordan NH. Circulating endothelial progenitor cells and erectile dysfunction:
possibility of nutritional intervention? Panminerva Med. 2010 Jun;52(2 Suppl
1):75-80. PMID: 20657539.

Wang H, Jin P, Sabatino M, Ren J, Civini S, Bogin V, Ichim TE, Stroncek DF.
Comparison of endometrial regenerative cells and bone marrow stromal cells. J
Transl Med. 2012 Oct 5;10:207. doi: 10.1186/1479-5876-10-207. PMID: 23038994;
PMCID: PMC3504519.

Zheng X, Suzuki M, Ichim TE, Zhang X, Sun H, Zhu F, Shunnar A, Garcia B,
Inman RD, Min W. Treatment of autoimmune arthritis using RNA interference-
modulated dendritic cells. J Immunol. 2010 Jun 1;184(11):6457-64. doi:
10.4049/jimmunol.0901717. Epub 2010 Apr 30. PMID: 20435931.

Dasanu CA, Clark BA 3rd, Ichim TE, Alexandrescu DT. Polycystic ovary
syndrome: focus on platelets and prothrombotic risk. South Med J. 2011
Mar;104(3):174-8. doi: 10.1097/SMJ.0b013e31820c0172. PMID: 21297528.

Mikirova NA, Kesari S, Ichim TE, Riordan NH. Effect of Infla-Kine
supplementation on the gene expression of inflammatory markers in peripheral
mononuclear cells and on C-reactive protein in blood. J Transl Med. 2017 Oct
20;15(1):213. doi: 10.1186/s12967-017-1315-4. PMID: 29058588; PMCID: PMC5651612.

Lu S, Shi G, Xu X, Wang G, Lan X, Sun P, Li X, Zhang B, Gu X, Ichim TE, Wang
H. Human endometrial regenerative cells alleviate carbon tetrachloride-induced
acute liver injury in mice. J Transl Med. 2016 Oct 22;14(1):300. doi:
10.1186/s12967-016-1051-1. PMID: 27770815; PMCID: PMC5075169.

Ichim TE, Li S, Ma H, Yurova YV, Szymanski JS, Patel AN, Kesari S, Min WP,
Wagner SC. Induction of tumor inhibitory anti-angiogenic response through
immunization with interferon Gamma primed placental endothelial cells:
ValloVax™. J Transl Med. 2015 Mar 14;13:90. doi: 10.1186/s12967-015-0441-0.
PMID: 25889119; PMCID: PMC4363400.

Suzuki M, Zheng X, Zhang X, Ichim TE, Sun H, Kubo N, Beduhn M, Shunnar A,
Garcia B, Min WP. Inhibition of allergic responses by CD40 gene silencing.
Allergy. 2009 Mar;64(3):387-97. doi: 10.1111/j.1398-9995.2008.01839.x. Epub 2009
Jan 28. PMID: 19175598.

Dasanu CA, Clark BA 3rd, Lahiri B, Ichim TE, Alexandrescu DT. Small cell
lung cancer with paraneoplastic lipase production. South Med J. 2010
Aug;103(8):819-22. doi: 10.1097/SMJ.0b013e3181e6369e. PMID: 20622741.

Riordan NH, Madrigal M, Reneau J, de Cupeiro K, Jiménez N, Ruiz S, Sanchez
N, Ichim TE, Silva F, Patel AN. Scalable efficient expansion of mesenchymal stem
cells in xeno free media using commercially available reagents. J Transl Med.
2015 Jul 17;13:232. doi: 10.1186/s12967-015-0561-6. PMID: 26183703; PMCID:

Zhang X, Beduhn M, Zheng X, Lian D, Chen D, Li R, Siu LK, Marleau A, French
PW, Ichim TE, Min WP. Induction of alloimmune tolerance in heart transplantation
through gene silencing of TLR adaptors. Am J Transplant. 2012
Oct;12(10):2675-88. doi: 10.1111/j.1600-6143.2012.04196.x. Epub 2012 Jul 23.
PMID: 22823145.

Ichim TE, Patel AN, Shafer KA. Experimental support for the effects of a
probiotic/digestive enzyme supplement on serum cholesterol concentrations and
the intestinal microbiome. J Transl Med. 2016 Jun 22;14(1):184. doi:
10.1186/s12967-016-0945-2. PMID: 27333764; PMCID: PMC4918082.

Han X, Meng X, Yin Z, Rogers A, Zhong J, Rillema P, Jackson JA, Ichim TE,
Minev B, Carrier E, Patel AN, Murphy MP, Min WP, Riordan NH. Inhibition of
intracranial glioma growth by endometrial regenerative cells. Cell Cycle. 2009
Feb 15;8(4):606-10. doi: 10.4161/cc.8.4.7731. Epub 2009 Mar 2. PMID: 19197154.

Suzuki M, Zheng X, Zhang X, Zhang ZX, Ichim TE, Sun H, Nakamura Y, Inagaki
A, Beduhn M, Shunnar A, Garcia B, Min WP. A novel allergen-specific therapy for
allergy using CD40-silenced dendritic cells. J Allergy Clin Immunol. 2010
Mar;125(3):737-43, 743.e1-743.e6. doi: 10.1016/j.jaci.2009.11.042. PMID:

Mikirova NA, Ichim TE, Riordan NH. Anti-angiogenic effect of high doses of
ascorbic acid. J Transl Med. 2008 Sep 12;6:50. doi: 10.1186/1479-5876-6-50.
PMID: 18789157; PMCID: PMC2562367.

Suzuki M, Zheng X, Zhang X, Ichim TE, Beduhn ME, Min W. Oligonucleotide
based-strategies for allergy with special reference to siRNA. Expert Opin Biol
Ther. 2009 Apr;9(4):441-50. doi: 10.1517/14712590902841924. PMID: 19344281.

Meng X, Ichim TE, Zhong J, Rogers A, Yin Z, Jackson J, Wang H, Ge W, Bogin
V, Chan KW, Thébaud B, Riordan NH. Endometrial regenerative cells: a novel stem
cell population. J Transl Med. 2007 Nov 15;5:57. doi: 10.1186/1479-5876-5-57.
PMID: 18005405; PMCID: PMC2212625.

Jiang N, Zhang X, Zheng X, Chen D, Zhang Y, Siu LK, Xin HB, Li R, Zhao H,
Riordan N, Ichim TE, Quan D, Jevnikar AM, Chen G, Min W. Targeted gene silencing
of TLR4 using liposomal nanoparticles for preventing liver ischemia reperfusion
injury. Am J Transplant. 2011 Sep;11(9):1835-44. doi:
10.1111/j.1600-6143.2011.03660.x. Epub 2011 Jul 27. PMID: 21794086.

Zhong Z, Patel AN, Ichim TE, Riordan NH, Wang H, Min WP, Woods EJ, Reid M,
Mansilla E, Marin GH, Drago H, Murphy MP, Minev B. Feasibility investigation of
allogeneic endometrial regenerative cells. J Transl Med. 2009 Feb 20;7:15. doi:
10.1186/1479-5876-7-15. PMID: 19232091; PMCID: PMC2649897.

Zhong Z, Kusznieruk KP, Popov IA, Riordan NH, Izadi H, Yijian L, Sher S,
Szczurko OM, Agadjanyan MG, Tullis RH, Harandi A, Reznik BN, Mamikonyan GV,
Ichim TE. Induction of antitumor immunity through xenoplacental immunization. J
Transl Med. 2006 May 25;4:22. doi: 10.1186/1479-5876-4-22. PMID: 16725035;
PMCID: PMC1482718.

Ichim TE, Solano F, Lara F, Paris E, Ugalde F, Rodriguez JP, Minev B, Bogin
V, Ramos F, Woods EJ, Murphy MP, Patel AN, Harman RJ, Riordan NH. Feasibility of
combination allogeneic stem cell therapy for spinal cord injury: a case report.
Int Arch Med. 2010 Nov 11;3:30. doi: 10.1186/1755-7682-3-30. PMID: 21070647;
PMCID: PMC2989319.

Chen S, Wei Q, Li J, Xiang Y, Guo H, Ichim TE, Chen S, Chen G. A simple and
reliable method to blood type monkeys using serum samples. Transpl Int. 2009
Oct;22(10):999-1004. doi: 10.1111/j.1432-2277.2009.00859.x. Epub 2009 Mar 9.
PMID: 19298252.

Zhong Z, Dong Z, Lu Q, Li Y, Lv C, Zhu X, Zhao X, Zhang X, Morales F, Ichim
TE. Successful penile replantation with adjuvant hyperbaric oxygen treatment.
Urology. 2007 May;69(5):983.e3-5. doi: 10.1016/j.urology.2007.02.024. PMID:

Alexandrescu DT, Ichim TE, Kabigting F, Dasanu CA. Acute gout during
treatment with paclitaxel for metastatic melanoma. Rheumatology (Oxford). 2009
Jul;48(7):862-3. doi: 10.1093/rheumatology/kep123. Epub 2009 May 20. PMID:

Ichim TE, Zhong R, Min WP. Prevention of allograft rejection by in vitro
generated tolerogenic dendritic cells. Transpl Immunol. 2003 Jul-
Sep;11(3-4):295-306. doi: 10.1016/S0966-3274(03)00048-0. PMID: 12967783.

Dasanu CA, Ichim TE, Alexandrescu DT. Muehrcke's lines (Leukonychia striata)
due to transretinoic acid therapy for acute promyelocytic leukemia. J Oncol
Pharm Pract. 2013 Dec;19(4):377-9. doi: 10.1177/1078155212468923. Epub 2013 Jan
4. PMID: 23292969.

Dasanu CA, Bauer F, Ichim TE, Vyas D, Ek K, Alexandrescu DT. Rapidly fatal
acute ATLL emerging after methotrexate therapy for disseminated psoriasis. Clin
Lymphoma Myeloma Leuk. 2012 Feb;12(1):76-8. doi: 10.1016/j.clml.2011.02.010.
Epub 2011 Jun 11. PMID: 21729685.

Xia X, Zhang X, Huang X, Ichim TE, Li M, Luke P, Min W. Anti-CD(45)RB
monoclonal antibody induces immunologic toleration by suppressing dendritic
cells. Transpl Immunol. 2009 Jul;21(3):136-9. doi: 10.1016/j.trim.2009.04.001.
Epub 2009 Apr 21. PMID: 19389475.

Feng B, Chen G, Zheng X, Sun H, Zhang X, Zhang ZX, Xiang Y, Ichim TE, Garcia
B, Luke P, Jevnikar AM, Min WP. Small interfering RNA targeting RelB protects
against renal ischemia-reperfusion injury. Transplantation. 2009 May
15;87(9):1283-9. doi: 10.1097/TP.0b013e3181a1905e. PMID: 19424026.

Yang WZ, Zhang Y, Wu F, Min WP, Minev B, Zhang M, Luo XL, Ramos F, Ichim TE,
Riordan NH, Hu X. Safety evaluation of allogeneic umbilical cord blood
mononuclear cell therapy for degenerative conditions. J Transl Med. 2010 Aug
3;8:75. doi: 10.1186/1479-5876-8-75. PMID: 20682053; PMCID: PMC2922090.

Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP. Tumor
exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol
Dis. 2005 Sep-Oct;35(2):169-73. doi: 10.1016/j.bcmd.2005.07.001. PMID: 16081306.

Zheng X, Vladau C, Zhang X, Suzuki M, Ichim TE, Zhang ZX, Li M, Carrier E,
Garcia B, Jevnikar AM, Min WP. A novel in vivo siRNA delivery system
specifically targeting dendritic cells and silencing CD40 genes for
immunomodulation. Blood. 2009 Mar 19;113(12):2646-54. doi:
10.1182/blood-2008-04-151191. Epub 2009 Jan 22. PMID: 19164600.

Mikirova NA, Jackson JA, Hunninghake R, Kenyon J, Chan KW, Swindlehurst CA,
Minev B, Patel AN, Murphy MP, Smith L, Ramos F, Ichim TE, Riordan NH.
Nutraceutical augmentation of circulating endothelial progenitor cells and
hematopoietic stem cells in human subjects. J Transl Med. 2010 Apr 8;8:34. doi:
10.1186/1479-5876-8-34. PMID: 20377846; PMCID: PMC2862021.

Kanai N, Min WP, Ichim TE, Wang H, Zhong R. Th1/Th2 xenogenic antibody
responses are associated with recipient dendritic cells. Microsurgery.
2007;27(4):234-9. doi: 10.1002/micr.20342. PMID: 17477419.

Dasanu CA, Mesologites T, Homsi S, Ichim TE, Alexandrescu DT. Chronic
lymphocytic leukemia presenting with cholecystitis-like symptoms and gallbladder
wall invasion. South Med J. 2010 May;103(5):482-4. doi:
10.1097/SMJ.0b013e3181d7e38f. PMID: 20375943.

Yang WZ, Zhang Y, Wu F, Zhang M, Cho SC, Li CZ, Li SH, Shu GJ, Sheng YX,
Zhao N, Tang Y, Jiang S, Jiang S, Gandjian M, Ichim TE, Hu X. Human umbilical
cord blood-derived mononuclear cell transplantation: case series of 30 subjects
with hereditary ataxia. J Transl Med. 2011 May 16;9:65. doi:
10.1186/1479-5876-9-65. PMID: 21575250; PMCID: PMC3112442.

Jiang N, Zhang X, Zheng X, Chen D, Siu K, Wang H, Ichim TE, Quan D,
McAlister V, Chen G, Min WP. A novel in vivo siRNA delivery system specifically
targeting liver cells for protection of ConA-induced fulminant hepatitis. PLoS
One. 2012;7(9):e44138. doi: 10.1371/journal.pone.0044138. Epub 2012 Sep 6. PMID:
22970170; PMCID: PMC3435394.

McKnight AL, Minkoff LA, Sutton DL, Thomsen BV, Habecker PL, Sweeney RW,
Smith G, Dasanu CA, Ichim TE, Alexandrescu DT, Stutman JM. Generalized cerebral
atrophy seen on MRI in a naturally exposed animal model for Creutzfeldt-Jakob
disease. J Transl Med. 2010 Nov 26;8:125. doi: 10.1186/1479-5876-8-125. PMID:
21108848; PMCID: PMC3009697.

Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X, Jiang N,
Navarro B, Ichim TE, Urquhart B, Min W. Silencing IDO in dendritic cells: a
novel approach to enhance cancer immunotherapy in a murine breast cancer model.
Int J Cancer. 2013 Feb 15;132(4):967-77. doi: 10.1002/ijc.27710. Epub 2012 Jul
20. PMID: 22870862.

Zheng X, Lian D, Wong A, Bygrave M, Ichim TE, Khoshniat M, Zhang X, Sun H,
De Zordo T, Lacefield JC, Garcia B, Jevnikar AM, Min WP. Novel small interfering
RNA-containing solution protecting donor organs in heart transplantation.
Circulation. 2009 Sep 22;120(12):1099-107, 1 p following 1107. doi:
10.1161/CIRCULATIONAHA.108.787390. Epub 2009 Sep 8. PMID: 19738144.

Zhu M, Zhang W, Liu F, Wang L, Liu B, Chen D, Zhu XH, Zhang WJ, Ichim TE,
Chen ZS, Zhou P, Chen S, Chen G. Resistance to anti-xenogeneic response by
combining alpha-Gal silencing with HO-1 upregulation. Transpl Immunol. 2008
Jul;19(3-4):202-8. doi: 10.1016/j.trim.2008.06.002. Epub 2008 Jul 1. PMID:

Chan RC, Gutierrez B, Ichim TE, Lin F. Enhancement of DNA cancer vaccine
efficacy by combination with anti-angiogenesis in regression of established
subcutaneous B16 melanoma. Oncol Rep. 2009 Nov;22(5):1197-203. doi:
10.3892/or_00000555. PMID: 19787240.

Yin Z, Chen D, Hu F, Ruan Y, Li J, Wang L, Xiang Y, Xie L, Wang X, Ichim TE,
Chen S, Chen G. Cotransplantation with xenogenetic neonatal porcine sertoli
cells significantly prolongs islet allograft survival in nonimmunosuppressive
rats. Transplantation. 2009 Aug 15;88(3):339-45. doi:
10.1097/TP.0b013e3181ae5dcf. PMID: 19667935.

Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH,
Riordan NH, Koropatnick J, Bogin V, Minev BR, Min WP, Tullis RH. Exosomes as a
tumor immune escape mechanism: possible therapeutic implications. J Transl Med.
2008 Jul 22;6:37. doi: 10.1186/1479-5876-6-37. PMID: 18644158; PMCID:

Li J, Gong Q, Zhong S, Wang L, Guo H, Xiang Y, Ichim TE, Wang CY, Chen S,
Gong F, Chen G. Neutralization of the extracellular HMGB1 released by ischaemic
damaged renal cells protects against renal ischaemia-reperfusion injury. Nephrol
Dial Transplant. 2011 Feb;26(2):469-78. doi: 10.1093/ndt/gfq466. Epub 2010 Aug
2. PMID: 20679140.

Ichim TE, Popov IA, Riordan NH, Izadi H, Zhong Z, Yijian L, Sher S, Oleinik
EK. A novel method of modifying immune responses by vaccination with lipiodol-
siRNA mixtures. J Transl Med. 2006 Jan 3;4:2. doi: 10.1186/1479-5876-4-2. PMID:
16390542; PMCID: PMC1343589.

Wang H, Ge W, Arp J, Zassoko R, Liu W, Ichim TE, Jiang J, Jevnikar AM,
Garcia B. Free bone graft attenuates acute rejection and in combination with
cyclosporin a leads to indefinite cardiac allograft survival. J Immunol. 2009
May 15;182(10):5970-81. doi: 10.4049/jimmunol.0801037. PMID: 19414748.

Popov I, Li M, Zheng X, San H, Zhang X, Ichim TE, Suzuki M, Feng B, Vladau
C, Zhong R, Garcia B, Strejan G, Inman RD, Min WP. Preventing autoimmune
arthritis using antigen-specific immature dendritic cells: a novel tolerogenic
vaccine. Arthritis Res Ther. 2006;8(5):R141. doi: 10.1186/ar2031. PMID:
16911769; PMCID: PMC1779442.

Yin Z, Wang L, Xiang Y, Ruan Y, Li J, Wang X, Ichim TE, Chen S, Chen G.
Resistance of neonatal porcine Sertoli cells to human xenoantibody and
complement-mediated lysis is associated with low expression of alpha-Gal and
high production of clusterin and CD59. Xenotransplantation. 2010 May-
Jun;17(3):215-23. doi: 10.1111/j.1399-3089.2010.00581.x. PMID: 20636542.

Dougherty CJ, Ichim TE, Liu L, Reznik G, Min WP, Ghochikyan A, Agadjanyan
MG, Reznik BN. Selective apoptosis of breast cancer cells by siRNA targeting of
BORIS. Biochem Biophys Res Commun. 2008 May 23;370(1):109-12. doi:
10.1016/j.bbrc.2008.03.040. Epub 2008 Mar 18. PMID: 18355444.

Hill JA, Ichim TE, Kusznieruk KP, Li M, Huang X, Yan X, Zhong R, Cairns E,
Bell DA, Min WP. Immune modulation by silencing IL-12 production in dendritic
cells using small interfering RNA. J Immunol. 2003 Jul 15;171(2):691-6. doi:
10.4049/jimmunol.171.2.691. Erratum in: J Immunol. 2003 Sep 15;171(6):3303.
PMID: 12847235.

Mansilla E, Spretz R, Larsen G, Nuñez L, Drago H, Sturla F, Marin GH, Roque
G, Martire K, Díaz Aquino V, Bossi S, Gardiner C, Lamonega R, Lauzada N, Cordone
J, Raimondi JC, Tau JM, Biasi NR, Marini JE, Patel AN, Ichim TE, Riordan N,
Maceira A. Outstanding survival and regeneration process by the use of
intelligent acellular dermal matrices and mesenchymal stem cells in a burn pig
model. Transplant Proc. 2010 Dec;42(10):4275-8. doi:
10.1016/j.transproceed.2010.09.132. PMID: 21168681.

Suzuki M, Zheng X, Zhang X, Li M, Vladau C, Ichim TE, Sun H, Min LR, Garcia
B, Min WP. Novel vaccination for allergy through gene silencing of CD40 using
small interfering RNA. J Immunol. 2008 Jun 15;180(12):8461-9. doi:
10.4049/jimmunol.180.12.8461. PMID: 18523314.

Zhang X, Li M, Lian D, Zheng X, Zhang ZX, Ichim TE, Xia X, Huang X, Vladau
C, Suzuki M, Garcia B, Jevnikar AM, Min WP. Generation of therapeutic dendritic
cells and regulatory T cells for preventing allogeneic cardiac graft rejection.
Clin Immunol. 2008 Jun;127(3):313-21. doi: 10.1016/j.clim.2008.01.013. Epub 2008
Mar 20. PMID: 18358783.

Min WP, Zhou D, Ichim TE, Strejan GH, Xia X, Yang J, Huang X, Garcia B,
White D, Dutartre P, Jevnikar AM, Zhong R. Inhibitory feedback loop between
tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J
Immunol. 2003 Feb 1;170(3):1304-12. doi: 10.4049/jimmunol.170.3.1304. PMID:

Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH,
Agadjanyan MG. Antitumor efficacy of DNA vaccination to the epigenetically
acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J
Cell Biochem. 2006 Aug 1;98(5):1037-43. doi: 10.1002/jcb.20953. PMID: 16741971.

Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Dasanu CA. IFN-
conditioned dendritic cells for the therapy of melanoma: what is missing? J
Immunother. 2011 Oct;34(8):607-609. doi: 10.1097/CJI.0b013e31822b9ffc. PMID:
22025902; PMCID: PMC3184394.

Wang H, Hosiawa KA, Min W, Yang J, Zhang X, Garcia B, Ichim TE, Zhou D,
Lian D, Kelvin DJ, Zhong R. Cytokines regulate the pattern of rejection and
susceptibility to cyclosporine therapy in different mouse recipient strains
after cardiac allografting. J Immunol. 2003 Oct 1;171(7):3823-36. doi:
10.4049/jimmunol.171.7.3823. PMID: 14500684.

Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N,
Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG. Elicitation of T cell
responses to histologically unrelated tumors by immunization with the novel
cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol.
2007 Jan 1;178(1):566-73. doi: 10.4049/jimmunol.178.1.566. PMID: 17182597;
PMCID: PMC2377412.

Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH,
Lobanenkov VV, Agadjanyan MG. DNA, but not protein vaccine based on mutated
BORIS antigen significantly inhibits tumor growth and prolongs the survival of
mice. Gene Ther. 2008 Jan;15(1):61-4. doi: 10.1038/ Epub 2007 Nov
1. PMID: 17972923; PMCID: PMC2497453.

Mamikonyan G, Kiyatkin A, Movsesyan N, Mkrtichyan M, Ghochikyan A,
Petrushina I, Hwang J, Ichim TE, Keledjian H, Agadjanyan MG. Detection of the
active components of calf thymus nuclear proteins (TNP), histones that are
binding with high affinity to HIV-1 envelope proteins and CD4 molecules. Curr
HIV Res. 2008 Jun;6(4):318-26. doi: 10.2174/157016208785132545. PMID: 18691030.

Yang J, Bernier SM, Ichim TE, Li M, Xia X, Zhou D, Huang X, Strejan GH,
White DJ, Zhong R, Min WP. LF15-0195 generates tolerogenic dendritic cells by
suppression of NF-kappaB signaling through inhibition of IKK activity. J Leukoc
Biol. 2003 Sep;74(3):438-47. doi: 10.1189/jlb.1102582. PMID: 12949248.

Min WP, Zhou D, Ichim TE, Xia X, Zhang X, Yang J, Huang X, Garcia B,
Dutartre P, Jevnikar AM, Strejan GH, Zhong R. Synergistic tolerance induced by
LF15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic
cells. Transplantation. 2003 Apr 27;75(8):1160-5. doi:
10.1097/01.TP.0000061792.78914.52. PMID: 12717196.

Khandaker MH, Kadhim SA, Ichim TE, Howson-Jan K, Chin J, Singhal SK.
Prevention of bladder tumor formation in mice by a novel bone marrow-derived
factor, reptimed. Anticancer Res. 2000 Jan-Feb;20(1A):183-9. PMID: 10769653.
Last edited by TimGDixon on Wed Feb 17, 2021 2:46 am, edited 1 time in total.
Posts: 1312
Joined: Fri Jun 26, 2020 8:27 am

In Vitro Cytotoxicity Testing of CAR-T Cells from Charles River

Post by curncman »

In Vitro Cytotoxicity Testing of CAR-T Cells from Charles River

Post Reply